FDA warning letter received by subsidiary of ZOLL

October 15, 2014
Asahi Kasei Corp.

On September 23, 2014, a subsidiary of ZOLL Medical Corporation (ZOLL) received a warning letter* from the U.S. Food and Drug Administration (FDA) regarding the LifeVest™ wearable defibrillator. The letter was posted on the FDA website on October 14, 2014, as reported in the media today.

ZOLL takes all correspondence from the FDA seriously, and is making progress toward addressing the concerns raised in the letter. Asahi Kasei believes that this matter will not have a significant effect on ZOLL’s LifeVest™ business or Asahi Kasei’s consolidated financial performance.


Adobe Readeris required to view these PDF files.

page top